Assessment of local angiogenesis and vascular endothelial growth factor in the patients with atrophic-erosive and reticular oral lichen planus

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 103, Issue 5, 2007, Pages 661-669

  Tao, Xiaoan ^a   Huang, Yulei ^a   Li, Ruyao ^a   Qing, Ronghui ^a   Ma, Li ^a   Rhodus, Nelson L ^b   Cheng, Bin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Institute for Molecular Virology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; VASCULOTROPIN A;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; CAPILLARY; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ENZYME IMMUNOASSAY; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; LICHEN PLANUS; MALE; METABOLISM; MIDDLE AGED; MOUTH MUCOSA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PILOT STUDY; TONGUE; VASCULARIZATION;

ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD34; CAPILLARIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; TONGUE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247329042     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.05.023     Document Type: Article

References (68)

1. Lodi G., Scully C., Carrozzo M., Griffiths M., Sugerman P.B., and Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2005) 40-51
2. Lodi G., Scully C., Carrozzo M., Griffiths M., Sugerman P.B., and Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 (2005) 164-178
3. Dissemond J. Oral lichen planus: an overview. J Dermatolog Treat 15 (2004) 136-140
4. Bagan-Sebastian J.V., Milian-Masanet M.A., Penarrocha-Diago M., and Jimenez Y. A clinical study of 205 patients with oral lichen planus. J Oral Maxillofac Surg 50 (1992) 116-118
5. Pezelj-Ribaric S., Prso I.B., Abram M., Glazar I., Brumini G., and Simunovic-Soskic M. Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm 13 (2004) 131-133
6. Seoane J., Romero M.A., Varela-Centelles P., Diz-Dios P., and Garcia-Pola M.J. Oral lichen planus: a clinical and morphometric study of oral lesions in relation to clinical presentation. Braz Dent J 15 (2004) 9-12
7. Sklavounou-Andrikopoulou A., Chrysomali E., Iakovou M., Garinis G.A., and Karameris A. Elevated serum levels of the apoptosis related molecules TNF-alpha, Fas/Apo-1 and Bcl-2 in oral lichen planus. J Oral Pathol Med 33 (2004) 386-390
8. Carmeliet P. Angiogenesis in health and diseases. Nat Med 9 (2003) 653-660
9. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptor. Nat Med 9 (2003) 669-676
10. Cornelini R., Artese L., Rubini C., Fioroni M., Ferrero G., Santinelli A., et al. Vascular endothelial growth factor and microvessel density around healthy and failing dental implants. Int J Oral Maxillofac Implants 16 (2001) 389-393
11. Creamer D., Sullivan D., Bicknell R., and Barker J. Angiogenesis in psoriasis. Angiogenesis 5 (2002) 231-236
12. Bonnet C.S., and Walsh D.A. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (2005) 7-16
13. Szekanecz Z., Gaspar L., and Koch A.E. Angiogenesis in rheumatoid arthritis. Front Biosci 10 (2005) 1739-1753
14. Kirk S., Frank J.A., and Karlik S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon?. J Neurol Sci 217 (2004) 125-130
15. Watanabe H., Mamelak A.J., Wang B., Howell B.G., Freed I., Esche C., et al. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol 13 (2004) 671-681
16. Koutroubakis I.E., Xidakis C., Karmiris K., Sfiridaki A., Kandidaki E., and Kouroumalis E.A. Serum angiogenin in inflammatory bowel disease. Dig Dis Sci 49 (2004) 1758-1762
17. Hern S., Stanton A.W., Mellor R.H., Harland C.C., Levick J.R., and Mortimer P.S. In vivo quantification of the structural abnormalities in psoriatic microvessels before and after pulsed dye laser treatment. Br J Dermatol 152 (2005) 505-511
18. Yamakawa T., Sudo A., Tanaka M., and Uchida A. Microvascular density of rapidly destructive arthropathy of the hip joint. J Orthop Surg (Hong Kong) 13 (2005) 40-45
19. Jin Y., Tipoe G.L., White F.H., and Yang L. A quantitative investigation of immunocytochemically stained blood vessels in normal, benign, premalignant and malignant human oral cheek epithelium. Virchows Arch 427 (1995) 145-151
20. Tipoe G.L., Jin Y., and White F.H. The relationship between vascularity and cell proliferation in human normal and pathological lesions of the oral cheek epithelium. Eur J Cancer B Oral Oncol 32B (1996) 24-31
21. Khan A., Farah C.S., Savage N.W., Walsh L.J., Harbrow D.J., and Sugerman P.B. Th1 cytokines in oral lichen planus. J Oral Pathol Med 32 (2003) 77-83
22. Rhodus N.L., Cheng B., Myers S., Bowles W., Ho V., and Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 114 (2005) 278-283
23. Rhodus N.L., Cheng B., Myers S., Miller L., Ho V., and Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 44 (2005) 77-82
24. Simark-Mattsson C., Bergenholtz G., Jontell M., Eklund C., Seymour G.J., Sugerman P.B., et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 44 (1999) 499-507
25. Mignogna M.D., Fedele S., Lo Russo L., Lo Muzio L., and Bucci E. Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence?. Oral Oncology 40 (2004) 120-130
26. Karatsaidis A., Schreurs O., Helgeland K., Axell T., and Schenck K. Erythematous and reticular forms of oral lichen planus and oral lichenoid reactions differ in pathological features related to disease activity. J Oral Pathol Med 32 (2003) 275-281
27. Mignogna M.D., Lo Russo L., Fedele S., Ruoppo E., Califano L., and Lo Muzio L. Clinical behaviour of malignant transforming oral lichen planus. Eur J Surg Oncol 28 (2002) 838-843
28. Rodriguez-Nunez I., Blanco-Carrion A., Garcia A.G., and Rey J.G. Peripheral T-cell subsets in patients with reticular and atrophic-erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91 (2001) 180-188
29. Baillie R., Harada K., Carlile J., Macluskey M., Schor S.L., and Schor A.M. Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. Histochem J 33 (2001) 287-294
30. Carlile J., Harada K., Baillie R., Macluskey M., Chisholm D.M., Ogden G.R., et al. Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. J Oral Pathol Med 30 (2001) 449-457
31. Singh M., Capocelli K.E., Marks J.L., Schleicher R.B., Finlayson C.A., and Seligman P.A. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. Appl Immunohistochem Mol Morphol 13 (2005) 147-156
32. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89 (1997) 881-886
33. Kyzas P.A., Stefanou D., and Agnantis N.J. Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip. Oral Oncology 40 (2004) 941-947
34. Cho C.S., Cho M.L., Min S.Y., Kim W.U., Min D.J., Lee S.S., et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 164 (2000) 5055-5061
35. Ju T., Brewer K., D'Souza A., Cummings R.D., and Canfield W.M. Cloning and expression of human core 1 beta1, 3-galactosyltransferase. J Biol Chem 277 (2002) 178-186
36. Viac J., Palacio S., Schmitt D., and Claudy A. Expression of vascular endothelial growth factor in normal epidermis, epithelial tumors and cultured keratinocytes. Arch Dermatol Res 289 (1997) 158-163
37. Lai W.K., and Adams D.H. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J Hepatol 42 (2005) 7-11
38. Edwards P.C., and Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc 68 (2002) 494-499
39. Eisman S., and Orteu C.H. Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment. Clin Exp Dermatol 29 (2004) 268-270
40. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
41. Creamer D., Allen M., Jaggar R., Stevens R., Bicknell R., and Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138 (2002) 791-796
42. Drouart M., Saas P., Billot M., Cedoz J.P., Tiberghien P., Wendling D., et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132 (2003) 158-162
43. Kirk S.L., and Karlik S.J. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 21 (2003) 353-363
44. Lee S.S., Joo Y.S., Kim W.U., Min D.J., Min J.K., Park S.H., et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19 (2001) 321-324
45. Proescholdt M.A., Jacobson S., Tresser N., Oldfield E.H., and Merrill M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61 (2002) 914-925
46. Doldi N., Origoni M., Bassan M., Ferrari D., Rossi M., and Ferrari A. Vascular endothelial growth factor. Expression in human vulvar neoplastic and nonneoplastic tissues. J Reprod Med 41 (1996) 844-848
47. Szpaderska A.M., Walsh C.G., Steinberg M.J., and Dipietro L.A. Distinct patterns of angiogenesis in oral and skin wounds. J Dent Res 84 (2005) 309-314
48. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 (1996) 736-741
49. Li J., Perrella M.A., Tsai J.C., Yet S.F., Hsieh C.M., Yoshizumi M., et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J Biol Chem 270 (1995) 308-312
50. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 269 (1994) 6271-6274
51. Bodolay E., Koch A.E., Kim J., Szegedi G., and Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 6 (2002) 357-376
52. Gravallese E.M., Pettit A.R., Lee R., Madore R., Manning C., Tsay A., et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 62 (2003) 100-107
53. Hafner C., Meyer S., Langmann T., Schmitz G., Bataille F., Hagen I., et al. Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. World J Gastroenterol 11 (2005) 4024-4031
54. Kuroda K., Sapadin A., Shoji T., Fleischmajer R., and Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116 (2001) 713-720
55. Beecken W.D., Engl T., Blaheta R., Bentas W., Achilles E.G., Jonas D., et al. Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis. Angiogenesis 7 (2004) 69-73
56. De Bandt M., Ben Mahdi M.H., Ollivier V., Grossin M., Dupuis M., Gaudry M., et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 171 (2003) 4853-4859
57. Ferrara N., Hillan K.J., and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333 (2005) 328-335
58. Grosios K., Wood J., Esser R., Raychaudhuri A., and Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 53 (2004) 133-142
59. Miotla J., Maciewicz R., Kendrew J., Feldmann M., and Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80 (2000) 1195-1205
60. Takahashi H., Kato K., Miyake K., Hirai Y., Yoshino S., and Shimada T. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 23 (2005) 455-461
61. Tong Y., Zhang X., Zhao W., Zhang Y., Lang J., Shi Y., et al. Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis. Eur J Pharmacol 494 (2004) 101-109
62. Yoo S.A., Bae D.G., Ryoo J.W., Kim H.R., Park G.S., Cho C.S., et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 174 (2005) 5846-5855
63. Yoshio Y., Miyazaki M., Abe K., Nishino T., Furusu A., Mizuta Y., et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66 (2004) 1677-1685
64. Camisa C., and Popovsky J.L. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol 136 (2000) 1442-1443
65. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
66. Macario-Barrel A., Balguerie X., and Joly P. Treatment of erosive oral lichen planus with thalidomide. Ann Dermatol Venereol 130 (2003) 1109-1112
67. Maender J.L., Krishnan R.S., Angel T.A., and Hsu S. Complete resolution of generalized lichen planus after treatment with thalidomide. J Drugs Dermatol 4 (2005) 86-88
68. Rhodus N.L., Cheng B., Bowles W., Myers S., Miller L., and Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 12 (2006) 112-116